Puma Biotechnology Inc., of Los Angeles, reported interim results from the phase II CONTROL trial testing the effects of adding budesonide or colestipol to loperamide prophylaxis to control diarrhea caused by Nerlynx (neratinib) in patients with HER2-positive early stage breast cancer who had completed trastuzumab-based adjuvant therapy.